Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Immunotherapy has dramatically improved the survival of patients with advanced or metastatic malignancies. Recent studies suggest that immunotherapy may increase the risk of hepatitis, whereas it may also induce functional cure of chronic hepatitis B virus (HBV) infection. We evaluated the incidence of hepatitis flare, HBV reactivation, hepatitis B surface antigen (HBsAg) seroclearance or seroreversion in patients with current or past HBV infection who had received immunotherapy. METHODS: This was a territory-wide observational cohort study in Hong Kong. We identified patients through electronic medical records based on the prescriptions of immune checkpoint inhibitors from July 1, 2014, to December 31, 2019. Patients who were HBsAg positive or HBsAg negative with results for antibody to hepatitis B surface or core antigen (anti-HBs or anti-HBc) were included. RESULTS: A total of 990 patients (397 HBsAg-positive, 593 HBsAg-negative with 482 anti-HBc and/or anti-HBs positive, and 111 both anti-HBc and anti-HBs negative) were identified. All of HBsAg-positive and 15.9% HBsAg-negative patients were put on oral antiviral treatment. Hepatitis flare (alanine aminotransferase >2 times of the upper limit of normal) occurred in 39.3% HBsAg-positive and 30.4% HBsAg-negative patients. High baseline alanine aminotransferase and combination of immunotherapy increased the risk of hepatitis. HBV reactivation (≥2 log increase in HBV DNA from baseline) occurred in 2 HBsAg-positive patients; HBsAg seroclearance and seroreversion was observed in 1 HBsAg-positive and 1 HBsAg-negative patient, respectively (<1%). DISCUSSION: Hepatitis flare occurs in approximately 40% of HBsAg-positive patients and 30% of HBsAg-negative patients during immunotherapy. HBV reactivation, HBsAg seroclearance, and HBsAg seroreversion are rare. Current or past HBV infection has no impact on the emergence of hepatic flare associated with immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This notion is supported by a study in Hong Kong, which showed that only 1 of the 482 patients with negative HBsAg, positive anti-HBc, and/or anti-HBs had HBV DNA detected after therapy using immune checkpoint inhibitors.28”
From Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients (2024) · cites this paper as [28]
Citations
Cites
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Zhang, X., Zhou, Y., Chen, C., Fang, W., Cai, X., Zhang, X., Zhao, M., Zhang, B., Jiang, W., Lin, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0808-5 · Cited by 185
Research works printed but not linked: 27
- 2018, Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study, Lancet Gastroenterol Hepatol, 3, 383, 10.1016/S2468-1253(18)30056-6 · DOI · Paper page
- Yip, 2017, Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance, J Hepatol, 67, 902, 10.1016/j.jhep.2017.06.019 · DOI
- Yip, 2019, HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues, J Hepatol, 70, 361, 10.1016/j.jhep.2018.10.014 · DOI · Paper page
- Yip, 2018, Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients, J Hepatol, 68, 63, 10.1016/j.jhep.2017.09.018 · DOI
- 2017, EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection, J Hepatol, 67, 370, 10.1016/j.jhep.2017.03.021 · DOI · Paper page
- Sarin, 2016, Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update, Hepatol Int, 10, 1, 10.1007/s12072-015-9675-4 · DOI · Paper page
- Yip, 2019, Current knowledge of occult hepatitis B infection and clinical implications, Semin Liver Dis, 39, 249, 10.1055/s-0039-1678728 · DOI
- Esteva, 2019, Immunotherapy and targeted therapy combinations in metastatic breast cancer, Lancet Oncol, 20, e175, 10.1016/S1470-2045(19)30026-9 · DOI · Paper page
- Gong, 2018, Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations, J Immunother Cancer, 6, 8, 10.1186/s40425-018-0316-z · DOI · Paper page
- Wong, 2019, Hepatic adverse events of immune checkpoint inhibitors: A territory-wide cohort study, Hepatology, 70, 1223A
- Likhitsup, 2019, Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials, Clin Liver Dis, 23, 401, 10.1016/j.cld.2019.04.002 · DOI
- Wong, 2018, Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B, J Hepatol, 69, 793, 10.1016/j.jhep.2018.05.009 · DOI
- Wong, 2020, Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure, J Hepatol, 72, 57, 10.1016/j.jhep.2019.08.023 · DOI
- Lai, 2018, Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E: A territorywide cohort study from 2000 to 2016, Clin Infect Dis, 67, 1278, 10.1093/cid/ciy234 · doi:10.1093/cid/ciy234
- Wong, 2017, Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: A propensity score weighted landmark analysis, Aliment Pharmacol Ther, 46, 1001, 10.1111/apt.14341 · DOI
- Tang, 2018, Comprehensive analysis of the clinical immuno-oncology landscape, Ann Oncol, 29, 84, 10.1093/annonc/mdx755 · DOI · Paper page
- Cheng, 2020, Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma, J Hepatol, 72, 307, 10.1016/j.jhep.2019.09.025 · DOI · Paper page
- Mondaca, 2020, Clinical implications of drug-induced liver injury in early-phase oncology clinical trials, Cancer, 126, 4967, 10.1002/cncr.33153 · DOI
- McGahey, 2017, Reviewing concomitant medications for participants in oncology clinical trials, Am J Health Syst Pharm, 74, 580, 10.2146/ajhp151052 · DOI
- Zhang, 2020, Histologic patterns of liver injury induced by anti-PD-1 therapy, Gastroenterol Rep (Oxf), 8, 50, 10.1093/gastro/goz044 · DOI
- Fisicaro, 2010, Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B, Gastroenterology, 138, 682, 10.1053/j.gastro.2009.09.052 · DOI · Paper page
- Cheng, 2011, Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases, J Rheumatol, 38, 181, 10.3899/jrheum.100692 · doi:10.3899/jrheum.100692
- Tsai, 2006, Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents, Dig Dis Sci, 51, 1627, 10.1007/s10620-006-9074-8 · doi:10.1007/s10620-006-9074-8
- Onozawa, 2005, Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection, Transplantation, 79, 616, 10.1097/01.TP.0000151661.52601.FB · DOI · Paper page
- Loomba, 2017, Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions, Gastroenterology, 152, 1297, 10.1053/j.gastro.2017.02.009 · DOI · Paper page
- Wong, 2019, Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B, Liver Int, 39, 271, 10.1111/liv.13953 · DOI
- Yip, 2020, Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China, Gastroenterology, 158, 215, 10.1053/j.gastro.2019.09.025 · DOI · Paper page
Cited by
Yoo, S., Lee, D., Shim, J. H., Kim, K. M., Lim, Y.-S., Lee, H. C., Yoo, C., Ryoo, B.-Y., & Choi, J. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.019 · Cited by 73
Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients
Zhao, X., Wang, Y., Lai, R., Wang, X., Yu, Y., Li, M., Zhao, H., Ma, Z., Li, M., Guo, T., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000235 · Cited by 12
Zeng, Y., Huang, J., Pang, J., Pan, S., Wu, Y., Jie, Y., Li, X., & Chong, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330644 · Cited by 9
Metadata
- Authors
- Wong, G. L.-H., Wong, V. W.-S., Hui, V. W.-K., Yip, T. C.-F., Tse, Y.-K., Liang, L. Y., Lui, R. N.-S., Mok, T. S.-K., Chan, H. L.-Y., & Chan, S. L.
- Affiliations
- Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong SAR, China;
- State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Venue
- American Journal of Gastroenterology
- Published
- 2021-01-28
- Volume
- 116
- Issue
- 6
- Pages
- 1274-1283
- ISSN
- 0002-9270
- 1572-0241
- Cited by
- 51
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. https://app.cochat.ai/papers/10.14309/ajg.0000000000001142
- The paper
- Wong, G. L.-H., Wong, V. W.-S., Hui, V. W.-K., Yip, T. C.-F., Tse, Y.-K., Liang, L. Y., Lui, R. N.-S., Mok, T. S.-K., Chan, H. L.-Y., & Chan, S. L. (2021). Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. American Journal of Gastroenterology. https://doi.org/10.14309/ajg.0000000000001142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.